James Graham, CEO of Recce Pharmaceuticals

CEO of Recce Pharmaceuticals

Articles by James Graham, CEO of Recce Pharmaceuticals

Gonorrhea bacteria 3d illustration (Adobe Stock 243500525 by sveta)

Revolutionary Antibiotic-Resistant Gonorrhea Treatment: A Possible Breakthrough with Recce 327

ByJames Graham, CEO of Recce Pharmaceuticals

January 11th 2024

With gonorrhea's rising antibiotic resistance, Recce 327 by Recce Pharmaceuticals emerges as a game-changer, showing 99% efficacy in preclinical trials and promising potential against antibiotic-resistant bacteria globally.

James Graham, CEO of Recce Pharmaceuticals

Articles by James Graham, CEO of Recce Pharmaceuticals

Revolutionary Antibiotic-Resistant Gonorrhea Treatment: A Possible Breakthrough with Recce 327

Latest Updated Articles

Trending on Infection Control Today

Beyond the Barnyard: How H5N1 Is Crossing Species—and Borders

Veteran Infection Preventionists Chat: What Are the Soft Skills That Make Strong IPs?

Motivating Leadership and the Team to Improve Employee Engagement, Reduce Burnout, and Build Career Paths